- Trial phase
- Approved
- Time to market
- Already approved and commercialized (since 2019 for initial indication)
- Why 4/10
- No single make-or-break binary catalyst is scheduled in the next ~12 months: Enhertu is already approved and generating multi-billion-dollar revenue. The nearest readout is DESTINY-Gastric04 (Phase 3, primary completion estimated Aug 2026), but this is a label-expansion trial in a competitive setting for a mega-cap stock. With no PDUFA or pivotal binary ahead, the impact score is capped at 4, a commercial-stage asset driving steady growth, not a binary event.
For investors in AZN, Enhertu is a mature commercial asset driving growth, not a binary catalyst. The next watchpoint is the readout of DESTINY-Gastric04 (Phase 3 in HER2+ gastric cancer, estimated primary completion Aug 2026). For VIVS/VivoSim Labs, the drug is not theirs, they merely tested it on a safety platform, so any trading thesis tied to trastuzumab deruxtecan should not involve VIVS stock.
Price Chart
Executive Summary
Trastuzumab deruxtecan (brand name Enhertu) is a blockbuster antibody-drug conjugate (ADC) developed by Daiichi Sankyo and co-commercialized globally with AstraZeneca (AZN on NYSE). It is already FDA- and EU-approved for multiple indications including HER2-positive and HER2-low breast cancer, HER2-positive gastric cancer, HER2-mutant non-small cell lung cancer, and as a tumor-agnostic therapy for HER2-positive solid tumors. In 2026 alone, it gained FDA approvals in the early-stage/curative-intent breast cancer setting, EU approval in first-line metastatic breast cancer, and a positive CHMP opinion for tumor-agnostic use in Europe. The filing hint pointing to VIVS/VivoSim Labs is incorrect, VIVS is a pre-revenue micro-cap that merely tested the drug on its safety platform, not the developer. For AZN, Enhertu is a major commercial growth driver but not a binary catalyst, contributing to steady revenue growth for a $242B mega-cap.
How It Works
An antibody-drug conjugate (ADC) that works like a guided missile. The 'antibody' part homes in on a protein called HER2 found on the surface of certain cancer cells (breast, lung, stomach, and others). Once attached, the drug releases a chemotherapy payload (deruxtecan, a topoisomerase I inhibitor) directly inside the cancer cell to kill it. Notably, it can also work on cells with low levels of HER2, not just those with high levels, expanding its reach far beyond older HER2-targeting drugs.
Trial Status
Multiple Phase 3 trials completed or active: DESTINY-Breast04 (completed, HER2-low breast cancer), DESTINY-Breast02 (completed, pretreated HER2+ breast cancer), DESTINY-Breast09 (active not recruiting, 1st-line HER2+ metastatic breast cancer, primary completion estimated Jul 2026), DESTINY-Gastric04 (active not recruiting, HER2+ gastric cancer, primary completion estimated Aug 2026), DESTINY-Lung04 (positive topline readout Aug 2026 for 1st-line HER2-mutant NSCLC). Multiple additional Phase 2/3 trials ongoing for earlier treatment lines and combination regimens.
The Two-Sided Case
Upcoming Catalysts
- DESTINY-Gastric04 Phase 3 topline readout (HER2+ gastric cancer, estimated primary completion Aug 2026)
- Potential further label expansions into additional tumor types
- EU regulatory decisions following CHMP positive opinions (adjuvant early breast cancer)
- Competitive dynamics as other HER2-directed ADCs and bispecifics advance through clinical trials
Source Filing
The SecBot filing or press-release report that triggered this drug report:
VivoSim Labs, Inc. Press Release VIVS ·Originating report